Figure 5.
Prognostic analysis 2. (A) 3-year DFS per patient age (years): ≤40, 78% (95% CI, 70-87); 41 to 55, 49% (95% CI, 37-66); > 55, 44% (95% CI, 30-66); P = .00052. (B) 3-year DFS per MRD risk model (n = 151 evaluable): MRDneg, 77% (95% CI, 70-86), MRDpos, 41% (95% CI, 26-64), P < .0001). (C) 3-year DFS per patient age (years) group and MRD risk model interactions: 18 to 40/MRDneg, 86% (95% CI, 78-95) vs >40/MRDpos, 65% (95% CI, 52-82) vs 18 to 40/MRDpos, 64% (95% CI, 43-95) vs >40/MRDpos, 25% (95% CI, 11-59); P < .0001. (D) 3-year EFS per Ph-like ALL gene signature in 88 patients with B-ALL who were evaluable: Ph-like, 23% (95% CI, 10-49) vs non–Ph-like, 68% (95% CI, 57-81). P = .00049.

Prognostic analysis 2. (A) 3-year DFS per patient age (years): ≤40, 78% (95% CI, 70-87); 41 to 55, 49% (95% CI, 37-66); > 55, 44% (95% CI, 30-66); P = .00052. (B) 3-year DFS per MRD risk model (n = 151 evaluable): MRDneg, 77% (95% CI, 70-86), MRDpos, 41% (95% CI, 26-64), P < .0001). (C) 3-year DFS per patient age (years) group and MRD risk model interactions: 18 to 40/MRDneg, 86% (95% CI, 78-95) vs >40/MRDpos, 65% (95% CI, 52-82) vs 18 to 40/MRDpos, 64% (95% CI, 43-95) vs >40/MRDpos, 25% (95% CI, 11-59); P < .0001. (D) 3-year EFS per Ph-like ALL gene signature in 88 patients with B-ALL who were evaluable: Ph-like, 23% (95% CI, 10-49) vs non–Ph-like, 68% (95% CI, 57-81). P = .00049.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal